Most published oral combo data to date has been in GT1. The idea NS5A inhibitors are weak (or won't work) in GT3 patients could be based on studies done as a stand alone class in combination with peg/riba. This overlooks any synergistic effects the class may have when combined with a nucleotide or a nuke+riba.
Market Data 
Markets 
AI
